Takeda Oncology
Dean Bottino is a prominent professional in the field of clinical translational modeling and simulation, currently serving as the Senior Scientific Director at Takeda Oncology since July 2013. Prior experience includes roles at Roche Pharmaceuticals as the Disease Therapeutic Area Modeling Leader and Head of Modeling & Simulation Oncology, where leadership focused on clinical modeling for oncology projects. At Novartis Pharmaceuticals, Dean served as Associate Director for Biology Modeling & Simulation, supporting the oncology business unit. Additional experience encompasses positions at BioAnalytics Group LLC, Physiome Sciences, and academic roles as a Postdoctoral Research Fellow at the University of California, Berkeley, and studies in Mathematics at the University of Utah. Dean Bottino earned a PhD in Applied Mathematics (Mathematical Biology) from Tulane University and a BA in Mathematics (Comparative Literature) from Hamilton College.
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.